2652.HK

Pharmaceutical manufacturer CF PharmTech Inc. (2652.HK) on Friday launched its Hong Kong IPO, seeking to raise about HK$601 million ($77 million) by selling 41.2 million shares for HK$14.75 apiece. The subscription period for shares will close on Oct. 2, with trading slated to begin on Oct. 8.

The company plans to use 40% of the IPO proceeds for R&D of its inhaled product candidates and for ongoing clinical initiatives. About 20% will go to preclinical programs for multiple pipeline candidates and technological platforms. Another 30% is earmarked for purchasing equipment and expanding and upgrading the company’s production management systems.

CF PharmTech reported revenue of nearly 610 million yuan last year, up 9% year-on-year. Its profit for the year totaled 21.09 million yuan, down 33.5%. Its first-quarter revenue this year reached 136 million yuan, down 2.7% year-over-year, while its profit for the period more than doubled to 12.82 million yuan.

By Lau Chi Hang

To subscribe to Bamboo Works weekly free newsletter, click here

Recent Articles

WeRide is enjoying a payoff from expanding its global taxi flee

Robotaxi rollout drives faster earnings pace at WeRide

The driverless technology company is enjoying a payoff from expanding its global taxi fleet, with quarterly revenues surging and losses continuing to shrink Key Takeaways: Third-quarter revenue more than doubled,…
Illustration of Luckin and Costa coffee being tasted

Luckin Coffee eyes global leap as China’s Double 11 loses its luster

Luckin could be preparing a bid for Costa Coffee. What's driving this potential deal, and what are its chances for success? And this year's Double 11 festival looks like a dud, with most big e-commerce companies failing to publish any big numbers. What does the future hold for this fast-fading shopping fest?